Electron Kebebew

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling
    Gustavo G Fernandez-Ranvier
    Department of Surgery, J David Gladstone Institutes Genomics Core Laboratory, University of California, San Francisco, CA 94143 1674, USA
    Arch Surg 143:841-6; discussion 846. 2008
  2. ncbi Id1 gene expression and regulation in human thyroid tissue
    Electron Kebebew
    University of California, San Francisco, Department of Surgery and UCSF Comprehensive Cancer Center, San Francisco, California 94143, USA
    Thyroid 15:522-30. 2005
  3. ncbi Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors
    Electron Kebebew
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 1674, USA
    Cancer 103:1330-5. 2005
  4. ncbi A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    Surgery 140:960-6; discussion 966-7. 2006
  5. ncbi ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy
    Electron Kebebew
    Endocrine Surgery and Oncology Program, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Ann Surg 242:353-61; discussion 361-3. 2005
  6. ncbi Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms
    Electron Kebebew
    Endocrine Surgery and Oncology Program, University of California, San Francisco Comprehensive Cancer Center, CA 94143 1674, USA
    Surgery 138:1102-9; discussion 1109-10. 2005
  7. ncbi Hereditary non-medullary thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, 1600 Divisadero Street C 342, San Francisco, CA 94143, USA
    World J Surg 32:678-82. 2008
  8. ncbi The prevalence and prognostic value of BRAF mutation in thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, San Francisco, California 94143 1674, USA
    Ann Surg 246:466-70; discussion 470-1. 2007
  9. ncbi Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, Box 1674, San Francisco, CA 94143 1674, USA
    World J Surg 30:872-8. 2006
  10. ncbi Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms
    Electron Kebebew
    Endocrine Surgery and Oncology Program, San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1674, USA
    Cancer 106:2592-7. 2006

Research Grants

Collaborators

Detail Information

Publications78

  1. ncbi Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling
    Gustavo G Fernandez-Ranvier
    Department of Surgery, J David Gladstone Institutes Genomics Core Laboratory, University of California, San Francisco, CA 94143 1674, USA
    Arch Surg 143:841-6; discussion 846. 2008
    ..The gene expression profiles of benign and malignant adrenocortical tumors are different...
  2. ncbi Id1 gene expression and regulation in human thyroid tissue
    Electron Kebebew
    University of California, San Francisco, Department of Surgery and UCSF Comprehensive Cancer Center, San Francisco, California 94143, USA
    Thyroid 15:522-30. 2005
    ....
  3. ncbi Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors
    Electron Kebebew
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 1674, USA
    Cancer 103:1330-5. 2005
    ..The authors analyzed prognostic factors and treatment outcomes in patients with ATC reported in the National Cancer Institute's Surveillance, Epidemiology, and End Results data base...
  4. ncbi A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    Surgery 140:960-6; discussion 966-7. 2006
    ..Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that has been shown to induce differentiation, cell cycle arrest, and apoptosis in a variety of human cancers including thyroid cancer...
  5. ncbi ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy
    Electron Kebebew
    Endocrine Surgery and Oncology Program, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Ann Surg 242:353-61; discussion 361-3. 2005
    ..The objective of this study was to determine whether genes that regulate cellular invasion and metastasis are differentially expressed and could serve as diagnostic markers of malignant thyroid nodules...
  6. ncbi Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms
    Electron Kebebew
    Endocrine Surgery and Oncology Program, University of California, San Francisco Comprehensive Cancer Center, CA 94143 1674, USA
    Surgery 138:1102-9; discussion 1109-10. 2005
    ....
  7. ncbi Hereditary non-medullary thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, 1600 Divisadero Street C 342, San Francisco, CA 94143, USA
    World J Surg 32:678-82. 2008
    ..It is likely that emerging molecular approaches may help identify the gene or genes involved in HNMTC which would have important clinical ramifications...
  8. ncbi The prevalence and prognostic value of BRAF mutation in thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, San Francisco, California 94143 1674, USA
    Ann Surg 246:466-70; discussion 470-1. 2007
    ..To examine the prevalence of BRAF mutation among thyroid cancer histologic subtypes and determine the association of BRAF mutation with indicators of poor prognosis for papillary thyroid cancer and patient outcome...
  9. ncbi Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, Box 1674, San Francisco, CA 94143 1674, USA
    World J Surg 30:872-8. 2006
    ..Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival...
  10. ncbi Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms
    Electron Kebebew
    Endocrine Surgery and Oncology Program, San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1674, USA
    Cancer 106:2592-7. 2006
    ..The purpose of the current study was to determine the accuracy of novel candidate diagnostic markers to distinguish benign from malignant thyroid neoplasms, and to predict the extent of disease...
  11. ncbi Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels
    Electron Kebebew
    Department of Surgery, Mount Zion Medical Center, University of California San Francisco, San Francisco, California 94143, USA
    Cancer 109:1078-81. 2007
    ..The objective of this study was to determine whether a gradient in Tg protein level exists in patients with DTC...
  12. ncbi Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells
    Electron Kebebew
    San Francisco Comprehensive Cancer Center, University of California, San Francisco, California 94143 1674, USA
    J Clin Endocrinol Metab 89:6105-11. 2004
    ....
  13. ncbi Locally advanced differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, UCSF Mount Zion Medical Center, 513 Parnassus, S 343, San Francisco, CA 94143 1674, USA
    Surg Oncol 12:91-9. 2003
    ..Patients with microscopic or small gross residual disease, after surgical resection, may benefit from postoperative external radiotherapy for local control of disease...
  14. ncbi Parathyroidectomy for primary hyperparathyroidism in octogenarians and nonagenarians: a plea for early surgical referral
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, CA 94143 1674, USA
    Arch Surg 138:867-71. 2003
    ....
  15. ncbi Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy
    Electron Kebebew
    Department of Surgery, University of California, San Francisco 94143 1674, USA
    Arch Surg 139:974-7. 2004
    ..Patients with tertiary hyperparathyroidism (THPT) commonly have parathyroid hyperplasia and should have a bilateral neck exploration with subtotal or total parathyroidectomy with autotransplantation to obtain long-term cure...
  16. ncbi Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results?
    Dina M Elaraj
    Department of Surgery, Feinberg School of Medicine, Northwestern University, 676 N St Clair St, Ste 650, Chicago, IL 60611, USA
    Arch Surg 145:578-81. 2010
    ..Additional imaging studies are useful to select patients who are candidates for minimally invasive parathyroidectomy, and referral is not indicated when results from a preoperative sestamibi scan are negative...
  17. ncbi Nonfunctioning parathyroid carcinoma: case report and review of literature
    Gustavo G Fernandez Ranvier
    Department of Surgery, University of California, San Francisco, California, USA
    Endocr Pract 13:750-7. 2007
    ..To report a case of nonfunctioning parathyroid carcinoma that was incidentally found during a thyroidectomy for multinodular goiter...
  18. ncbi Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid
    Insoo Suh
    Department of Surgery, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143 0470, USA
    Am J Surg 200:41-6. 2010
    ..However, some clinicians measure preoperative Tg as a diagnostic cancer marker despite lack of supporting evidence. We examined whether Tg accurately predicts malignancy in follicular or Hürthle-cell neoplasms...
  19. ncbi Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms
    Electron Kebebew
    San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA 94143 1674, USA
    World J Surg 30:767-74. 2006
    ..We hypothesized that genes that regulate cell-cycle progression would be differentially expressed in malignant versus benign thyroid nodules and could serve as diagnostic markers and markers of disease aggressiveness...
  20. ncbi Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers
    Daniel T Ruan
    Department of Surgery, University of California, San Francisco, San Francisco, Calif, USA
    Surgery 144:908-13; discussion 913-4. 2008
    ..The purpose of this study was to determine if Mig-6 expression is associated with EGFR expression or surgical outcomes in PTC...
  21. ncbi Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation
    Willieford Moses
    Department of Surgery, University of California, San Francisco, California 94143, USA
    J Surg Res 160:179-83. 2010
    ..There is a significant gender and age disparity in thyroid cancer incidence and outcome. The molecular basis for these divergent clinical presentations and outcome are essentially unknown...
  22. ncbi Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy
    Willieford Moses
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    World J Surg 34:2589-94. 2010
    ..To determine the clinical utility of genetic testing in thyroid FNA biopsy, we conducted a prospective clinical trial...
  23. ncbi Is adrenal venous sampling necessary in all patients with hyperaldosteronism before adrenalectomy?
    Rasa Zarnegar
    Department of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    J Vasc Interv Radiol 19:66-71. 2008
    ..To evaluate whether selective rather than universal use of adrenal vein sampling (AVS) may be warranted in patients with hyperaldosteronism to characterize and lateralize disease before adrenalectomy...
  24. ncbi Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas
    Wen T Shen
    Department of Surgery, University of California San Francisco, Hellman Building C3 47, 1600 Divisadero Street, San Francisco, CA 94143, USA
    Surgery 136:1129-37. 2004
    ..The aim of this study was to determine if pheochromocytoma size should affect the choice of surgical approach...
  25. ncbi Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
    Cord Sturgeon
    Department of Surgery, University of California, San Francisco, USA
    J Am Coll Surg 202:423-30. 2006
    ..The recent NIH consensus conference did not make a definitive recommendation about management of 4- to 6-cm nonfunctioning incidentalomas...
  26. ncbi Prospective evaluation of the rate and impact of hemolysis on intraoperative parathyroid hormone (IOPTH) assay results
    Jacob Moalem
    Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA
    Ann Surg Oncol 17:2963-9. 2010
    ..Retrospective evidence suggested that hemolysis may artificially lower IOPTH results. Falsely decreased IOPTH measurements could result in either failed parathyroidectomy or unnecessary bilateral neck exploration...
  27. ncbi Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid
    Rebecca S Sippel
    Department of Surgery, University of California San Francisco and the UCSF Comprehensive Cancer Center at Mount Zion, San Francisco, CA 94143, USA
    World J Surg 32:702-7. 2008
    ..We sought to determine if the primary tumor size correlated with the risk of malignancy in patients with a preoperative FNA diagnosis of a Hürthle cell neoplasm...
  28. ncbi Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California San Francisco UCSF, San Francisco, California 94143, USA
    Thyroid 19:953-6. 2009
    ..We investigated the efficacy and side effects of rosiglitazone therapy in patients with differentiated thyroid cancer of follicular cell origin that fails to take up radioiodine or is unresectable...
  29. ncbi Clinical and molecular features of papillary thyroid cancer in adolescents and young adults
    Menno R Vriens
    Department of Surgery, University of California at San Francisco, San Francisco, California, USA
    Cancer 117:259-67. 2011
    ..In this study, the authors compared the molecular and clinical features of papillary thyroid cancer (PTC) in AYAs with the same features among patients in other age groups...
  30. ncbi Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?
    Gustavo G Fernandez-Ranvier
    Department of Surgery, University of California at San Francisco, San Francisco, California 94143 1674, USA
    Cancer 110:255-64. 2007
    ..Parathyroid carcinoma, atypical parathyroid adenoma, and parathyromatosis can be differentiated relatively easily from typical parathyroid adenomas, but distinguishing them from each other is more difficult...
  31. ncbi Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid?
    Rebecca S Sippel
    Department of Surgery, University of California San Francisco, and the UCSF Comprehensive Cancer Center at Mount Zion, San Francisco, CA 94143 1674, USA
    Surgery 142:851-7; discussion 857.e1-2. 2007
    ..We sought to determine whether the presence of additional thyroid nodules on preoperative ultrasound decreased the risk of malignancy in a patient with a follicular neoplasm...
  32. ncbi Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer
    Yevgeniya Kushchayeva
    Department of Surgery, University of California San Francisco, UCSF Mt Zion Medical Center, 1600 Divisadero Street C347, San Francisco, CA 94143 1674, USA
    Am J Surg 195:457-62. 2008
    ..Hurthle cell cancer (HCC) is considered by some to be a variant of follicular cancer (FC), but many think it is a distinct histologic tumor with a more aggressive behavior...
  33. ncbi Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families
    Insoo Suh
    Department of Surgery, University of California, San Francisco, CA, USA
    Surgery 146:1073-80. 2009
    ..We aimed to identify loci linked to FNMTC susceptibility using single-nucleotide polymorphism (SNP) array-based linkage analysis in a broad sampling of affected families...
  34. ncbi Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13
    Gustavo G Fernandez-Ranvier
    Department of Surgery, University of California, San Francisco, School of Medicine, UCSF Mt Zion Medical Center, 1600 Divisadero Street, San Francisco, CA 94143 1674, USA
    World J Surg 32:873-81. 2008
    ..As genes on this chromosome may be important in the pathogenesis of adrenocortical carcinoma, we compared their expression profile between benign and malignant adrenocortical tissue...
  35. ncbi Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model
    Electron Kebebew
    Comprehensive Cancer Center and Department of Surgery, University of California, San Francisco, USA
    Arch Surg 141:777-82; discussion 782. 2006
    ....
  36. ncbi The helix-loop-helix protein, Id-1, is overexpressed and regulates growth in papillary thyroid cancer
    Electron Kebebew
    Department of Surgery Department of Pathology, University of California, San Francisco, CA 94143, USA
    Surgery 134:235-41. 2003
    ..Furthermore, deregulated expression of Id proteins has been observed in some human malignancies. Therefore we hypothesized that the Id-1 gene may play a role in papillary thyroid carcinogenesis...
  37. ncbi Metastatic papillary thyroid cancer misdiagnosed as non-small [corrected] cell lung cancer
    Jacob Moalem
    Division of Surgical Oncology, Department of Surgery, University of Rochester, Rochester, New York 14642, USA
    Thyroid 21:319-23. 2011
    ..As thyroid cancers commonly spread to the lungs, metastatic thyroid cancer should be included in the differential diagnosis of a pulmonary lesion or lesions...
  38. ncbi Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease
    Frederic Triponez
    Endocrine Surgical Oncology, University of California Mount Zion Medical Center, CA 94143 1674, USA
    J Clin Endocrinol Metab 91:4943-7. 2006
    ..Surgical excision of nonpalpable recurrent thyroid cancer can be difficult, particularly in a previously operated area...
  39. ncbi Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection
    Rebecca S Sippel
    Department of Surgery, University of Wisconsin Madison, Madison, WI, USA
    World J Surg 33:434-9. 2009
    ..The goal of this study was to evaluate the utility of preincision ultrasound-guided injection of blue dye into the abnormal lymph nodes to facilitate their safe and efficient removal...
  40. ncbi Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling
    Insoo Suh
    Department of Surgery, University of California, San Francisco, CA 94143 1674, USA
    Ann Surg 250:983-90. 2009
    ..To improve our understanding of the molecular mechanisms involved in malignant pheochromocytoma by examining differences in the gene expression profile between benign and malignant tumors...
  41. ncbi Does routine consultation of thyroid fine-needle aspiration cytology change surgical management?
    Yah Y Tan
    Department of Surgery, University of California, San Francisco, San Francisco, CA 94143 1674, USA
    J Am Coll Surg 205:8-12. 2007
    ..We sought to determine the concordance rates between FNA interpretations at referring institutions and our center to determine if they alter surgical management...
  42. ncbi GCMB gene, a master regulator of parathyroid gland development, expression, and regulation in hyperparathyroidism
    Electron Kebebew
    Department of Surgery, University of California San Francisco, Box 1674, San Francisco, CA 94143, USA
    Surgery 136:1261-6. 2004
    ..The glial cell missing gene, GCMB , encodes a transcription factor, which is a master regulator of parathyroid development. We postulated that the GCMB gene might play a role in parathyroid tumorigenesis in hyperparathyroidism...
  43. ncbi Defining a molecular phenotype for benign and malignant parathyroid tumors
    Gustavo G Fernandez-Ranvier
    Department of Surgery, University of California at San Francisco, San Francisco, California 94143 1674, USA
    Cancer 115:334-44. 2009
    ....
  44. ncbi Patterns of antibiotic prophylaxis use for thyroidectomy and parathyroidectomy: results of an international survey of endocrine surgeons
    Jacob Moalem
    Department of Surgery, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Am Coll Surg 210:949-56. 2010
    ..Although cervical endocrine operations are classified as clean cases, and prophylactic antibiotics (pABX) are generally not indicated, practice patterns vary...
  45. ncbi Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?
    Daniel Shibru
    Department of Surgery, University of California at San Francisco, San Francisco, California 94143 1674, USA
    Cancer 113:930-5. 2008
    ..The aim of the current study was to determine the diagnostic accuracy of the 3-gene assay in thyroid tissue and in FNA biopsy for distinguishing benign from malignant thyroid neoplasms...
  46. ncbi Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes
    Jennifer B Ogilvie
    Department of Surgery, Endocrine Surgery and Oncology Program, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143, USA
    J Natl Compr Canc Netw 4:139-47. 2006
    ..This review covers the diagnosis, evaluation, timing of surgical management, and optimal follow-up of patients with hereditary medullary thyroid cancer syndromes...
  47. ncbi The number of needle passes affects the accuracy of parathyroid hormone assay with intraoperative parathyroid aspiration
    Marlon A Guerrero
    Department of Surgery, University of Arizona, Tucson, AZ 85724, USA
    Am J Surg 200:701-5; discussion 705-6. 2010
    ..However, the reported aspiration technique varies in the literature. We sought to determine if the number of passes affected the accuracy of PTH analysis...
  48. ncbi Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma
    James Lee
    Endocrine Surgery Department, University of California, San Francisco, California, USA
    Thyroid 17:367-9. 2007
  49. ncbi Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations
    Wen T Shen
    Department of Surgery, University of California, San Francisco Mt Zion Medical Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Arch Surg 145:272-5. 2010
    ..Critics of this approach argue that reoperative CLND has higher complication and recurrence rates than initial CLND. We sought to test this argument, using it as our hypothesis...
  50. ncbi Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer
    Willieford Moses
    School of Medicine, University of California, San Francisco, California, USA
    Thyroid 21:367-71. 2011
    ..Patients with FNMTC present at a younger age. Somatic mutations and extent of disease are similar in sporadic and FNMTC cases...
  51. ncbi Do patients undergoing parathyroidectomy for primary hyperparathyroidism in San Francisco, CA, and Bursa, Turkey, differ?
    Turkay Kirdak
    Department of Surgery, University of California at San Francisco Mount Zion Medical Center, San Francisco, CA, USA
    Am J Surg 198:188-92. 2009
    ....
  52. ncbi Multiple endocrine neoplasia type 2
    Michael E Gertner
    Department of Surgery, University of California San Francisco, 1600 Divisadero Street, C3-47, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 5:315-25. 2004
    ..Patients with familial MTC may have not manifested the other features of MEN-2A, thus these patients should have continued follow-up for pheochromocytoma and primary hyperparathyroidism...
  53. ncbi Gene-expression profiling of adrenocortical carcinoma
    Insoo Suh
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    Expert Rev Mol Diagn 9:343-51. 2009
    ..In this article, we discuss the limitations of the clinical management of ACC, and the gene-expression profile studies that have attempted to address these limitations...
  54. ncbi Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors
    Chung J Hung
    Endocrine Surgical Oncology Fellows, University of California San Francisco, California 94143, USA
    J Clin Endocrinol Metab 88:3694-9. 2003
    ..The lymphangiogenic role of VEGF-C in thyroid cancers therefore appears to be complex and other factors are likely to be also involved...
  55. ncbi Observation or laparoscopic adrenalectomy for adrenal incidentaloma? A surgical decision analysis
    Laurent Brunaud
    Department of Surgery, University California San Francisco and Mount Zion Medical Center, Mount Zion Medical Center, San Francisco, CA, USA
    Med Sci Monit 12:CR355-62. 2006
    ..A decision analysis model was used to identify relevant variables for selecting the optimal management (observation versus adrenalectomy)...
  56. ncbi The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma
    Rasa Zarnegar
    Department of Surgery, Weill Cornell Medical College, New York, NY 10021, USA
    Ann Surg 247:511-8. 2008
    ..To develop a prediction model using information readily available, at clinical presentation, which could determine whether patients with aldosterone-producing adenomas would have complete resolution of hypertension after adrenalectomy...
  57. ncbi Extent of disease and practice patterns for medullary thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, San Francisco, CA 94143-1674, USA
    J Am Coll Surg 200:890-6. 2005
    ..A high proportion of patients continue to receive less than optimal initial surgical treatment...
  58. ncbi Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells
    Wen T Shen
    Department of Surgery, Endocrine Surgery Laboratory, UCSF/Mt. Zion Medical Center, San Francisco, CA 94143-1674, USA
    Surgery 138:979-84; discussion 984-5. 2005
    ..These findings suggest that VA may be useful clinically for patients with thyroid cancers of follicular cell origin...
  59. ncbi Malignant pheochromocytoma
    Rasa Zarnegar
    Department of Surgery, University California San Francisco, Comprehensive Cancer Center at Mount Zion, Medical Center, 1600 Divisadero Street, Hellman Building, Room C347, San Francisco, CA 94143 1764, USA
    Surg Oncol Clin N Am 15:555-71. 2006
    ....
  60. ncbi Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells
    Insoo Suh
    Department of Surgery and Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143 1674, USA
    Arch Surg 145:226-32. 2010
    ..Decitabine recovers expression of silenced genes on chromosome 11q13 and has antineoplastic effects in adrenocortical carcinoma (ACC) cells...
  61. ncbi Calciphylaxis: rare but fatal
    Amarjit Dosanjh
    Department of Surgery, University of California-San Francisco, Mount Zion Medical Center, San Francisco, CA, USA
    Curr Surg 62:455-8. 2005
  62. ncbi Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma
    Mehmet Haciyanli
    Department of Surgery, University of California San Francisco/Mount Zion Medical Center, San Francisco, CA, USA
    J Am Coll Surg 197:739-46. 2003
    ..The combined accuracy of US, sestamibi, and IOPTH assay predicted a double adenoma in 80% of the patients...
  63. ncbi Hemolysis falsely decreases intraoperative parathyroid hormone levels
    Jacob Moalem
    University of California, San Francisco, CA, USA
    Am J Surg 197:222-6. 2009
    ..Falsely decreased IOPTH measurements could result in false-negative or false-positive results and lead to failed parathyroidectomy or unnecessary additional exploration...
  64. ncbi Prognostic indications for Hürthle cell cancer
    Yevgeniya Kushchayeva
    Endocrine Surgical Oncology, Department of Surgery, University of California-San Francisco/Mount Zion Medical Center, 1600 Divisadero Street, San Francisco, CA 94143-1674, USA
    World J Surg 28:1266-70. 2004
    ..Disease-free survivals were 65.0% and 40.5% at 5 and 10 years, respectively. Our findings show that gender and stage of disease influence the prognosis of patients with HCC...
  65. ncbi Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: review of 261 laparoscopic adrenalectomies from 1993 to 2003
    Wen T Shen
    Department of Surgery, University of California, San Francisco/Mt Zion Medical Center, San Francisco, California 94143-1674, USA
    World J Surg 28:1176-9. 2004
    ..All eight of the tumors removed were at least 5 cm in size (range 5-16 cm). The mean length of hospitalization was 4.4 days (range 3-8 days)...
  66. ncbi Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation
    Frederic Triponez
    Division of Endocrine Surgical Oncology, University of California at San Francisco, San Francisco, CA, USA
    Surgery 140:990-7; discussion 997-9. 2006
    ..The optimal surgical approach for tertiary hyperparathyroidism (HPT) after kidney transplantation is unknown. Existing studies are limited by small sample size, lack of adjustment for kidney function, and no long-term follow-up...
  67. ncbi Predictors of airway complications after thyroidectomy for substernal goiter
    Wen T Shen
    Department of Surgery, University of California, San Francisco, USA
    Arch Surg 139:656-9; discussion 659-60. 2004
    ..The few patients who developed postoperative airway complications were older, had larger goiters, and were more likely to have tracheal compression on preoperative imaging than those without airway complications...
  68. ncbi Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease?
    Geeta Lal
    Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Thyroid 15:569-74. 2005
    ..Total or near-total thyroidectomy obviates these disadvantages and can be performed without increased complication rates, thus appearing to be the preferred extent of thyroidectomy for Graves' disease...
  69. ncbi Recent developments in the clinical application of thyroid cancer biomarkers
    Daniel Shibru
    Department of Surgery, University of California, San Francisco, USA
    Curr Opin Oncol 20:13-8. 2008
    ..The aim of this article is to provide an update on the status of the clinical application of thyroid cancer biomarkers...
  70. ncbi Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer
    Menno R Vriens
    Department of Surgery, University of California, San Francisco, California, USA
    Thyroid 19:1343-9. 2009
    ..The goal of this article was to review our current knowledge on the hereditary nonmedullary thyroid cancer...
  71. ncbi Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors
    Karl Y Bilimoria
    Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 113:3130-6. 2008
    ..The authors' objectives were to examine treatment utilization and factors associated with long-term survival after resection of ACC in a large, national, patient population...
  72. ncbi Use of the electrothermal vessel sealing system versus standard vessel ligation in thyroidectomy
    Wen T Shen
    Department of Surgery, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Asian J Surg 28:86-9. 2005
    ..CONCLUSION: We found that the LigaSure was as safe as standard vessel ligation for thyroidectomy, with the benefit of reduced operating time. A future prospective study has been designed...
  73. ncbi Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the "subclinical" pheochromocytoma
    James A Lee
    Division of Gastrointestinal Endocrine Surgery, Columbia University Medical Center, New York, New York, USA
    Arch Surg 142:870-3; discussion 73-4. 2007
    ..To assess the risk of pheochromocytoma in patients with borderline-elevated urine or plasma metanephrine levels...
  74. ncbi Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers
    Ming Lang Shih
    Division of General Surgery, Department of Surgery, National Defense Medical Center, Taipei, Taiwan, R O C
    Thyroid 18:729-34. 2008
    ..The aim of this study was to determine the rate of complications and associated cancer in patients with Hashimoto's thyroiditis...
  75. ncbi Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases
    Wen T Shen
    Department of Surgery, University of California, San Francisco, USA
    Arch Surg 141:771-4; discussion 774-6. 2006
    ..Patients undergoing adrenalectomy for unilateral non-Cushing adrenal tumors do not require postoperative steroid replacement...
  76. ncbi Laparoscopic adrenalectomy for malignancy
    Cord Sturgeon
    Department of Surgery, University of California, San Francisco Comprehensive Cancer Center at Mount Zion Medical Center, 1600 Divisadero Street, Hellman Building, Room C3-47, San Francisco, California 94143-1674, USA
    Surg Clin North Am 84:755-74. 2004
    ..Laparoscopic adrenalectomy should be cautiously performed, with the goals of achieving complete tumor resection without disruption of the adrenal capsule...
  77. ncbi Does familial non-medullary thyroid cancer adversely affect survival?
    Frederic Triponez
    Advanced Research Technologies, Applied Biosystems, 850 Lincoln Center Drive, MS 447, Foster City, CA 94404 1105, USA
    World J Surg 30:787-93. 2006
    ..Familial non-medullary thyroid cancer (FNMTC) is associated with a higher rate of multifocality and a higher recurrence rate than sporadic thyroid cancer. However, the effect of FNMTC on life expectancy is unknown...
  78. ncbi Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms
    Electron Kebebew
    Department of Surgery, University of California, San Francisco 94121, USA
    Arch Surg 137:948-51; discussion 952-3. 2002
    ..Furthermore, preoperative fine-needle aspiration cytology for the evaluation of suspected malignant adrenal tumors is unreliable...

Research Grants1

  1. Extracellular matrix and protease markers of malignant thyroid neoplasm
    Electron Kebebew; Fiscal Year: 2007
    ..We will use these results to design a multicenter clinical trial evaluating the diagnostic and prognostic value of ECM1 and TMPRSS4 expression in patients with thyroid neoplasm. ..